Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
75.02
+0.16 (0.21%)
May 1, 2025, 4:00 PM EDT - Market closed
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Anish Bhatnagar |
Contact Details
Address: 100 Marine Parkway, Suite 400 Redwood City, California 94065 United States | |
| Phone | 650 213 8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| James H. MacKaness | Chief Financial Officer and Compliance Officer |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
| Jesse Schumaker | General Counsel |
| Lauren Budesheim | Vice President of People |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
| Dr. Mitchell Nagao M.B.A., Pharm.D. | Senior Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 144 | Filing |
| Mar 31, 2025 | SCHEDULE 13G/A | Filing |
| Mar 28, 2025 | 144 | Filing |
| Mar 28, 2025 | 144 | Filing |
| Mar 27, 2025 | 144 | Filing |